

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

The following list of claims will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

✓ 12. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to initial administration of a chemotherapeutic agent cisplatin, carboplatin or mitomycin, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said chemotherapeutic agent cisplatin, carboplatin or mitomycin, wherein said amount is a dosage in a range of 750 Units per kilogram to 2000 Units per kilogram.

13-18. (Canceled)

✓ 19. (Currently Amended) A method according to claim 12 [[15]], wherein said chemotherapeutic agent is administered intravenously.

✓ 20. (Currently Amended) A method according to claim 12, wherein said erythropoietin is administered intravenously or subcutaneously.

✓ 21. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to initial administration of cisplatin;

wherein said erythropoietin is administered in an endothelial-inhibiting amount of, ^{growth suppressing} wherein said amount is a dosage in a range from about 750 Units per kilogram to about 2,000 Units per kilogram.

22- 23. (Canceled)

24. (Previously Presented) A method according to claim 21, wherein said cisplatin is administered intravenously.

25. (Currently Amended) A method according to claim 21, wherein said erythropoietin is administered intravenously or subcutaneously.

26. (Currently Amended) A method according to claim 12 [[15]], wherein said chemotherapeutic agent cisplatin, carboplatin or mitomycin is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

27-30. (Canceled)

31. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a cerebellar hemangioblastoma.

32. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a ductal carcinoma of the breast.

33. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a squamous cell cancer of the larynx.

34. (Previously Presented) A method of treating a solid vascularized tumor according to claim 12, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.

Attorney Docket No. 5218-39B

In re: Anagnostou et al.

Serial No.: 09/525,797

Filed: March 15, 2000

Page 4

25. (Previously Presented) A method of treating a solid vascularized tumor according to claim 21, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.